The University of Salamanca participates in this ambitious project through the research group Experimental Hepatology and Drug Vectorization (HEVEPHARM), directed by José Juan García Marín and attached to IBSAL and CIBEREHD, in close collaboration with the General Digestive Surgery Service of the University Hospital of Salamanca, directed by Luis Muñoz-Bellvís, also a member of IBSAL.
Under the coordination of the professor of the Department of Physiology and Pharmacology of the USAL and member of HEVEPHARM Rocío I. Rodríguez Macías, the Salamancan scientists are working on the identification of non-invasive biomarkers for the early diagnosis and prediction of response to pharmacological treatment of cholangiocarcinoma, a liver cancer that is “rare, but with a very poor prognosis, partly due to the difficulty of detecting it in the early stages of its development, when it can still be treated surgically”, according to HEVEPHARM.
